Key Events This Week
16 Mar: Valuation shifts to fair amid strong sector performance
17 Mar: Stock rebounds with 1.22% gain following valuation update
19 Mar: Technical momentum shifts signal mixed outlook
20 Mar: Stock closes week higher at Rs.948.90 (+2.37%)

Alivus Life Sciences Ltd Technical Momentum Shifts Signal Mixed Outlook
2026-03-19 08:03:07Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and others, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.
Read full news article
Alivus Life Sciences Ltd is Rated Hold
2026-03-17 10:10:45Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of its performance and prospects.
Read full news article
Alivus Life Sciences Ltd Valuation Shifts to Fair Amid Strong Sector Performance
2026-03-16 08:01:23Alivus Life Sciences Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of early 2026. Despite this adjustment, the small-cap pharmaceutical and biotechnology firm continues to demonstrate solid operational metrics and a resilient market performance relative to broader indices, prompting a reassessment of its price attractiveness within a sector characterised by elevated multiples.
Read full news article
Alivus Life Sciences Ltd is Rated Hold
2026-03-06 10:10:44Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Alivus Life Sciences Ltd is Rated Hold
2026-02-23 10:11:12Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Alivus Life Sciences Ltd is Rated Hold
2026-02-22 10:10:41Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 February 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Alivus Life Sciences Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-02-19 08:02:18Alivus Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven by improved price-to-earnings and price-to-book ratios relative to its historical averages and peer group. This change has prompted an upgrade in its Mojo Grade from Sell to Hold, reflecting a more favourable outlook amid a challenging pharmaceutical sector backdrop.
Read full news article






